CCMG
EWTX icon

Connecticut Capital Management Group’s Edgewise Therapeutics EWTX Stock Holding History

Connecticut Capital Management Group’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$399K Sell
9,824
-15
-0.2% -$517 0.32% 60
2026
Q1 		$310K Hold
9,839
– – 0.29% 71
2025
Q4 		$244K Buy
+9,839
New +$198K 0.23% 86

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Connecticut Capital Management Group's EWTX Position: Q2 2026 in Review

Connecticut Capital Management Group reduced its Edgewise Therapeutics (EWTX) stake by 0.15% in Q2 2026, selling an estimated $517 and leaving 9,824 shares worth $399K. The position accounts for 0.32% of the portfolio, ranked #60.

Connecticut Capital Management Group first reported a position in EWTX in Q4 2025 and has held it in 3 quarters since. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Connecticut Capital Management Group held 9,824 shares of Edgewise Therapeutics worth $399K as of Q2 2026.
  • Connecticut Capital Management Group sold 15 Edgewise Therapeutics shares in Q2 2026, an estimated $517.
  • Edgewise Therapeutics made up 0.32% of Connecticut Capital Management Group's portfolio in Q2 2026, its #60 holding.
  • Connecticut Capital Management Group first reported a position in Edgewise Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Connecticut Capital Management Group's 13F filing for Q2 2026, filed 20 Jul 2026.